Thai national guidelines for the prevention of motherto-child transmission of HIV: March 2010

Asian Biomedicine

Volumn 4, Issue 4, 2010, Pages 529-540

  Phanuphak, Nittaya ^a   Lolekha, Rangsima ^b   Chokephaibulkit, Kulkanya ^c   Voramongkol, Nipunporn ^d   Boonsuk, Sarawut ^e   Limtrakul, Aram ^f   Limpanyalert, Piyawan ^g   Chasombat, Sanchai ^d   Thanprasertsuk, Sombat ^h   Leechawengwong, Manoon ⁱ  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b Global AIDS Program   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e Benjalak Hospital   (Thailand)

^f NAKORNPING HOSPITAL   (Thailand)

^g Bamrasnaradura Infectious Disease Institute   (Thailand)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ Thai AIDS Society   (Thailand)

Author keywords

HIV; Mother to child transmission; Thai guidelines

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ANEMIA; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CHILD; CONTRACEPTION; COUNSELING; FAMILY PLANNING; FEMALE; FIRST TRIMESTER PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANCY; LABOR; LIVER TOXICITY; LONG TERM CARE; MEDICAL CARE; PATIENT CARE; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PSYCHOLOGICAL ASPECT; PUERPERIUM; REVIEW; SEROLOGY; SINGLE DRUG DOSE; THAILAND; VAGINAL DELIVERY; VERTICAL TRANSMISSION; VIRUS INHIBITION;

EID: 77957943381     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: 10.2478/abm-2010-0067     Document Type: Review

References (24)

1. Department of Health. Guidelines of prevention of mother-to-child HIV transmission management and care for HIV-infected women and families. Department of Health, Ministry of Public Health, May 2007.
2. McIntyre JA, Martinson N, Gray GE, for the Trial 1413 Investigator Team. Single dose nevirapine combined with a short course of combivir for prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and infant resistant virus. Antivir Ther. 2005; 10 (suppl 1): S4.
3. Results of HIV Sero-surveillance, Thailand 1989-2008. Source: AIDS division, Bureau of Epidemiology, Department of Disease Control. Available at http:// epid.moph.go.th/.
4. Naiwatanakul T, Punsuwan N, Kullerk N, Faikratok W, Lolekha R, Sangwanloy O, et al. Reduction in HIV transmission risk following recommendations for CD4 testing to guide selection of prevention of mother-to-child (PMTCT) regimens, Thailand, 2006-2007. Presented at 5th International AIDS Society Conference on HIV Pathogenesis and Treatment. Capetown, 19-22 July 2009 (Abstract CDC019).
5. Health promotion project evaluation report in social and economic development agenda 9. (February 2007). Business printing office of veteran support organization publisher.
6. Ad hoc reporting of Saiyairak family project. Department of Health. Available at http://www. saiyairakhospital.com/newdemo/admin/user-report. html, Accessed Dec 23, 09.
7. Bureau of Health Promotion, Department of Health, Bureau of Epidemiology, Department of Disease Control, and Thailand MOPH-U.S. CDC collaboration. Presented at Meeting to report the National PMTCT Program Evaluation 2007, Bangkok, 2 February 2008.
8. WHO. Rapid advice. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. November 2009. http://www.who.int/hiv/ pub/mtct/advice/en/; Accessed 25 March, 2010.
9. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004; 351:217-28.
10. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS. 2007; 21 (Suppl 4): S65-71.
11. Health Intervention and Technology Assessment Program (HITAP). Cost benefit and feasibility study of HAART for prevention of mother-to-child HIV transmission in Thailand. Presented at Steering Group Committee of HIV/AIDS System Development, Bangkok, November, 2009.
12. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005; 19:795-9.
13. Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007; 44:371-6.
14. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006; 7: 338-44.
15. Kondo W, Carraro EA, Prandel E, Dias JM, Perini J, Macedo RL, et al. Nevirapine-induced side effects in pregnant women: experience of a Brazilian University Hospital. Braz J Infect Dis. 2007; 11:544-8.
16. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 2007; 8:357-66.
17. Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr. 2003; 142:47-52.
18. Russell VD, Jourdain G, Shapiro D, Ngo-Giang-Huong N, Frenkel L, Britto P, et al. A phase II study of the incidence of nevirapine resistance mutations in HIV-infected Thai women receiving a single intrapartum dose of NVP followed by a postpartum tail of ZDV/ddI or ZDV/ddI/LPV/r: IMPAACT P1032. Presented at 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February, 2009 (Abstract 95aLB).
19. de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 2008; 9:452-502.
20. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998; 339:1409-14.
21. Gonzalez-Tome MI, Ramos Amador JT, Guillen S, Solis I, Fernandez-Ibieta M, Munoz E, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med. 2008; 9:868-74.
22. Hitti J, Andersen J, McComsey G, Liu T, Melvin A, Smith L, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol. 2007; 196:331 e1-7.
23. Ramautarsing R, van der Lugt J, Phanuphak N, Gorowara M, Kerr S, Chuemchaitrakool A, et al. Standard dose generic lopinavir/ritonavir provides adequate lopinavir plasma levels during the 3rd trimester of pregnancy in Thai HIV-1 infected women. Presented at 11th Workshop on Clinical Pharmacology of HIV Therapy, Sorento, April, 2010 (Poster 9).
24. Cressy T, Jourdain G, Rawangban B, Yathavisuthi P, Varadisai S, Kongpanichkul R, et al, and the PHPT-5 Study Team. Pharmacokinetics of lopinavir boosted with ritonavir initiated during the third trimester of pregnancy in HIV-1-infected Thai women. Presented at 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February, 2010 (Abstract 906).